Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Participants With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)

NCT01906489 is registered in ClinicalTrials.gov with Akebia Therapeutics as lead sponsor.

NCT NCT01906489
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01906489 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Participants With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Lead sponsor
Akebia Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
July 23, 2013
Completion date
September 3, 2014
Enrollment
210 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

anemia, chronic kidney disease